Herlong H F, Hunter F M, Koff R S, Maddrey W C
J Clin Pharmacol. 1981 Nov-Dec;21(11):701-5. doi: 10.1002/j.1552-4604.1981.tb05687.x.
In a cooperative study by clinicians in three medical facilities, bumetanide was compared with furosemide in patients presenting with ascites, a complication of chronic liver disease. In an open, parallel, randomized trial, 43 patients received bumetanide and 16 patients received furosemide. They were treated for from one to 28 weeks. Weight loss and decrease in abdominal girth following diuretic action occurred in both groups but was statistically significant only in the bumetanide treated patients. Because of the small number of patients on furosemide, valid statistical analysis could not be obtained. No evidence of hepatic encephalopathy developed during this study, and only one patient on furosemide was discontinued as a result of severe electrolyte imbalance. Differences in changes of electrolytes and uric acid ere not statistically significant in the two groups. The majority of drug-related abnormalities were the result of the pharmacologic activity of the diuretic.
在三家医疗机构的临床医生开展的一项合作研究中,对布美他尼和呋塞米在患有腹水(慢性肝病的一种并发症)的患者中进行了比较。在一项开放、平行、随机试验中,43例患者接受布美他尼治疗,16例患者接受呋塞米治疗。他们接受了1至28周的治疗。两组患者在利尿作用后均出现体重减轻和腹围减小,但仅在接受布美他尼治疗的患者中具有统计学意义。由于接受呋塞米治疗的患者数量较少,无法进行有效的统计分析。在本研究期间未出现肝性脑病的证据,并且仅1例接受呋塞米治疗的患者因严重电解质失衡而停药。两组患者电解质和尿酸变化的差异无统计学意义。大多数与药物相关的异常是利尿剂药理活性的结果。